A Soy-Derived Immunostimulating Peptide Inhibits Etoposide-Induced Alopecia in Neonatal Rats  by Tsuruki, Takahiro et al.
A Soy-Derived Immunostimulating Peptide Inhibits
Etoposide-Induced Alopecia in Neonatal Rats
To the Editor:
Diverse bioactive peptides are released from proteins
(Brantl et al, 1979; Takahashi et al, 1994; Matoba et al,
1999). While determining the various pharmacological ef-
fects of bioactive peptides isolated from enzymatic digests
of food proteins, we found that soymetide-4, an immuno-
stimulating peptide derived from soy protein, protected
neonatal rats from etoposide-induced (hair loss) alopecia.
Alopecia induced by anticancer agents is a troublesome
side effect. Therefore, a substance preventing it was searched
for among food-derived peptides. Because of convenience
and reproducibility, the neonatal rat model is often used to
screen substances that prevent alopecia induced by anti-
cancer agents such as etoposide.
In the previous study, we isolated soymetide-13 (Met-
Ile-Thr-Leu-Ala-Ile-Pro-Val-Asn-Lys-Pro-Gly-Arg) from tryp-
sin digest of soybean protein as a peptide stimulating
phagocytosis in vitro by human polymorphonuclear leuko-
cytes (Tsuruki et al, 2003). Soymetide-13 is derived from
residues 173–185 of the soybean b-conglycinin a0 subunit,
and the Met residue at the N-terminus is essential for the
phagocytosis-stimulating activity. The in vitro system phago-
cytosis-stimulating activity of soymetide-13 was changed
by the deletion of residues at the C-terminus; soymetide-4
(Met-Ile-Thr-Leu) was the shortest peptide that had mini-
mum activity. We investigated, however, the effect of orally
given soymetide-4 on alopecia induced by chemotherapy,
since soymetide-4 was more effective than soymetide-13 in
oral experiments; in a model system testing tumor necrosis
factor a (TNFa) production after oral administration in mice,
soymetide-4 was more active than soymetide-13 (Tsuruki
et al, 2003).
Soymetides have weak affinity for the chemotactic peptide
formyl-Met-Leu-Phe (fMLP) receptor, and the phagocytosis-
stimulating activity is blocked by Boc-MLF, an antagonist
of the fMLP receptor (Tsuruki et al, 2003). Therefore, soym-
etides are agonists of the fMLP receptor even though they
are not formylated at their N-termini. Then, we also inves-
tigated whether fMLP alone exerts protective effects
against etoposide-induced alopecia. Experimental proto-
cols involving laboratory rats were approved by the ethical
committee of the Graduate School of Agriculture, Kyoto
University.
Soymetide-4 almost completely suppressed alopecia
induced by etoposide (Nippon Kayaku, Tokyo, Japan, 1.0 mg
per kg i.p. for 3 d) in neonatal Sprague-Dawley (SD) rats
(Japan SLC, Shizuoka, Japan) after oral administration at a
dose of 300 mg per kg for 8 consecutive days (Fig 1Aa–c).
Although the degree of alopecia induced by etoposide was
different in each experiment (Fig 1Aa–c), soymetide-4
always inhibited alopecia greatly.
Also, we assessed the effect of fMLP on etoposide-
induced alopecia. Although it was not effective after oral
administration, intraperitoneal injection of the compound
inhibited alopecia induced by etoposide (1.5 mg per kg i.p.
for 3 d) substantially at doses of 10 and 30 mg per kg (Fig
1B), and completely at a dose of 100 mg per kg (data not
shown).
fMLP was ineffective after oral administration (data not
shown), even though the affinity of fMLP for the fMLP
receptor is 15,000 times stronger than the affinity of
soymetide-4 for this receptor (Tsuruki et al, 2003), probably
due to the severely restricted permeability of N-formylpep-
tides through the intestinal mucosa (Ferry et al, 1989). This
is consistent with the fact that fMLP was also ineffective at
stimulating TNFa production after oral administration to
mice, while soymetide-4 was active under the same con-
ditions (Tsuruki et al, 2003).
As shown in Fig 2A, loss of hair, thinning of the skin layer
and thickening of the epidermis induced by etoposide were
also suppressed by oral administration of soymetide-4. The
shape of the hair follicles in rats given both etoposide and
soymetide-4 was normal. The etoposide-induced decrease
in hair number and skin layer thinning were also suppressed
by the administration of fMLP at a dose of 100 mg per kg
i.p. for 4 consecutive days. However, etoposide-induced
thickening of the epidermis was not inhibited by fMLP (Fig
2B). fMLP or soymetide-4 did not cause inflammatory in-
filtration of macrophages and granulocytes to skin tissues
under these conditions (Fig 2A, B).
Next, we examined the effects of soymetide-4 and fMLP
on alopecia induced by the anticancer drugs Ara-C (Kohjin,
Tokyo, Japan, 20 mg per kg i.p. for 7 d) and cyclophos-
phamide (Nacalai Tesque, Kyoto, Japan, 30 mg per kg i.p.
for 1 d). Ara-C-induced alopecia was suppressed by oral
administration of soymetide-4 (300 mg per kg for 7 d) or
intraperitoneal injection of fMLP (100 mg per kg for 7 d)
(Fig 1C). Loss of hair induced by Ara-C administration was
inhibited by soymetide-4 and fMLP to some extent. On the
Abbreviations: fMLP, N-formyl-methionyl-leucyl-phenylalanine;
FPR, formylpeptide receptor; FPRL1R, FPR-like 1 receptor; TNF,
tumor necrosis factor
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other hand, cyclophosphamide-induced alopecia was not
inhibited by soymetide-4 or fMLP (data not shown). These
results might be related to the fact that etoposide and Ara-C
are cell cycle-dependent anticancer drugs, while cyclopho-
sphamide is not.
There are subtypes in fMLP receptors: the formylpeptide
receptor (FPR) and the FPR-like 1 receptor (FPRL1R),
respectively (Murphy et al, 1992; Le et al, 2002). fMLP binds
Figure 1
Protective effects of soymetide-4 or fMLP against anticancer drug-induced alopecia. (A) Etoposide was injected at a dose of 1.0 mg per kg
intraperitoneally for 3 consecutive days to 11-d-old rats. Soymetide-4 was administered orally at a dose of 300 mg per kg for 8 consecutive days
beginning 5 d before the first etoposide injection (a–c). Pictures were taken 7 d after the last etoposide injection (A and B). (B) Etoposide was injected
at a dose of 1.5 mg per kg intraperitoneally for 3 consecutive days to 11-d-old rats. fMLP (10, 30 mg per kg) was administered intraperitoneally for 4
consecutive days beginning 1 d before the first etoposide injection. (C) Ara-C was injected at a dose of 20 mg per kg intraperitoneally for 7
consecutive days to 8-d-old rats. Soymetide-4 (300 mg per kg p.o.) or fMLP (100 mg per kg i.p.) was administered for 7 consecutive days
concurrently with the Ara-C injections. The picture was taken 3 d after the last Ara-C injection.
Figure2
(A) Light micrographs of hematoxylin—eosin-stained dorsal skin
sections from neonatal rats treated with saline (a), etoposide (1.0 mg
per kg i.p.  3) (b), or etoposide (1.0 mg per kg i.p.  3) þ soymetide-4
(300 mg per kg p.o.  8) (c). (B) Light micrographs of hematoxylin—
eosin-stained dorsal skin sections from neonatal rats treated with saline
(a), etoposide (1.5 mg per kg i.p.  3) (b), or etoposide (1.5 mg per kg
i.p.  3) þ fMLP (100 mg per kg p.o.  4) (c). Scale bars: 100 mm. Skin
sections were removed and fixed in a 4% para-formaldehyde
phosphate buffer solution (pH 7.4) 7d after the last etoposide injection.
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FPR at nanomolar concentrations, while it is protective
against anticancer drug-induced alopecia only at very high
doses. Thus, the anti-alopecia effect of fMLP might be
mediated by receptors other than FPR.
In this preliminary study, we found that soymetide-4 is an
orally effective anti-alopecia peptide. We are now designing
more potent orally effective anti-alopecia peptides by
modifying the structure of soymetide-4, since the effective
dose of soymetide-4 is too high. The anti-alopecia effect in
adult rats and human will be evaluated in these potent
derivatives.
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